Biagio Ricciuti, MD, PhD
@BRicciutiMD
Thoracic Medical Oncologist at @DanaFarber | @harvardmed #Immunotherapy #KRAS #BRAF #MET #LungCancer
What about the rare stuff? @BRicciutiMD sheds light in what to do in patients with AGAs that could potentially respond to IO, such as MET, BRAF and KRAS. And it would not be Biagio without an opinion on STK11/KEAP1 co-mutations. #ASCO25
The weekly @OncoAlert round up coverings the TOP of the week July 18-24, 2025 is out! 📬📬REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅News From Industry: FLAURA2 OS Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🫁🧬 ✅News From Industry: FLAURA2 Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in Prostate…
Grateful for the invite to join this amazing meeting with ✨ @PTarantinoMD, #PatLorusso, #IanKrop, & @thenasheffect at @NRGonc in Washington DC. Insightful discussions on ADC biomarkers & challenges in predicting efficacy and safety in #NSCLC. @OncoAlert @DanaFarber
ADC biomarkers are complex! @BRicciutiMD from @DanaFarber provides an outstanding overview of the lessons learned in thoracic oncology, highlighting challenges with predicting which patients actually benefit of specific ADCs. @NRGonc
Kicking off in <24h, the @NRGonc Summer Symposium on ADCs promises to be epic! With over 230 registered attendees and a world class faculty, it will allow to review the terrific evolutions of this drug class across oncology fields. Still time to register! nrgoncology.org/Summer2025Mtg/…
Biagio, it will be an honor to welcome you to our institution. I'll be on vacation, but you'll be warmly welcomed! @BRicciutiMD @OncoAlert #LCSM
NEOIPOWER (@LungCaJournal): In resectable stage II–IIIB #EGFR+ NSCLC, neoadjuvant icotinib + chemo led to an ORR of 83.3%, but MPR was just 6.7% with no pCR. Adds to growing evidence of limited pathologic response w/ TKIs in this setting.🚨 @OncoAlert lungcancerjournal.info/article/S0169-…
![BRicciutiMD's tweet card. Most surgically resected patients with non-small cell lung cancer (NSCLC) inevitably develop local recurrence or distant metastasis, leading to poor prognosis [1,2]. Compared with surgery alone,...](https://pbs.twimg.com/card_img/1947637583808245761/06HY-035?format=jpg&name=orig)
Check out the latest 🚨@OncoAlert 🚨 Round Up covering the TOP of the week July 11-17, 2025 by @weoncologists! & don’t forget to REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Highlights include: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…
Don’t miss the new @OncoAlert newsletter. REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week covering: ✅Update on FORTITUDE-101 (Industry) GEJ ✅ShortHER in #BreastCancer ✅U-BOMB Trial in Breast #Cancer ✅DADSPORT in #prostatecancer ✅KBP-2020 Study…
The OncoAlert🚨Newsletter Now Out !! Covering June 23-July 3, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅Update on FORTITUDE-101 (Industry) GEJ ✅ShortHER in #BreastCancer ✅U-BOMB Trial in Breast #Cancer ✅DADSPORT in…
Phase III AIM-HIGH trial (@LancetRespirMed) by @DavidRSpigel et al. reports that adjuvant chemotherapy in resected stage IA–IIA non-squamous #NSCLC patients with a high-risk 14-gene score increased 2-year disease-free survival from 79% to 96%. @OncoAlert thelancet.com/journals/lanre…
Join us tomorrow for a free webinar where #DrDongFei from @Stanford and I will discuss the role of STK11 & KEAP1 mutations in #NSCLC. From biology to therapeutic implications. @IASLC @DanaFarberNews @AMPath @DanaFarber Register: educate.amp.org/local/catalog/…
TOMORROW: Join us for a free webinar (Thursday, June 26) exploring the critical role of STK11 and KEAP1 mutations in non-small cell lung cancer. Register: educate.amp.org/local/catalog/…
Check out the latest 🚨OncoAlert🚨Newsletter Covering Jun 12-19, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week covering among others: ✅Association of HRR Alterations With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer…
The OncoAlert🚨Newsletter Now Out !! Covering Jun 12-19, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ✅Association of HRR Alterations With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer ✅Comorbidity Burden and Effectiveness of…
Don’t miss the @OncoAlert🚨newsletter #ASCO25 EDITION⭐️ REGISTER👉OncoAlert360.com OR buff.ly/48Xpgz0 @matteolambe @PGrivasMDPhD @cdanicas @tompowles1 @Uromigos @JaniceTNBCmets @scserendipity1 @amerseburger @Icro_Meattini @ErikaHamilton9 @stolaney1 @wearemedsir…
The @OncoAlert🚨NEWSLETTER ⭐️THE COMPLETE #ASCO25 EDITION⭐️ REGISTER👉OncoAlert360.com OR buff.ly/48Xpgz0 OUR PICKS FROM THE ENTIRE CONGRESS and Special VIDEO insights from our collaborators on specific trials OUT On MONDAY June 9, 2025 !! @matteolambe…
Such a privilege to listen to Dr. Crinò—my first mentor—reflecting on 20 years of progress in #LungCancer treatment, from targeted therapies to immunotherapies. A masterclass in science and dedication in #Ferrara 🇮🇹. @OncoAlert @DanaFarber @iascl
Don't miss this fantastic opportunity! Looking for you in Milan in July
Don't miss the opportunity to submit a clinical case (trainees and oncologist <40 yo) for the Yin & Yang Lung Cancer Masterclass! w/stellar faculty @NarjustFlorezMD @BenjaminBesseMD @JessicaJLinMD @marinagarassino @thenasheffect @PrelajArsela & many others! Travel and…
Clinical case submissions are now open for the Yin & Yang Lung Cancer Masterclass! July 11-12, 2025 in Milan, Italy <40? Oncologist, surgeon, or rad onc? Submit by June 15! Submit a case on one of the topics: 1️⃣ Multimodal Rx (resectable/LA NSCLC) 2️⃣ Adjuvant EGFR/ALK+ NSCLC 3️⃣…
Don't miss the opportunity to submit a clinical case (trainees and oncologist <40 yo) for the Yin & Yang Lung Cancer Masterclass! w/stellar faculty @NarjustFlorezMD @BenjaminBesseMD @JessicaJLinMD @marinagarassino @thenasheffect @PrelajArsela & many others! Travel and…
With the best at #ASCO25 Last day and then Boston and/or Italy And our Brazilian transplant Dr. @MarceloCorassa Early stage session with a focus on target mutations
Many thanks to @VJOncology for featuring our study comparing immunotherapy to BRAF and MEK inhibitors for the first-line treatment of patients with BRAF V600E mutant NSCLC @IASLC @myESMO @BRicciutiMD @mvnegrao @DanaFarber @MDAndersonNews @MSKCancerCenter vjoncology.com/video/wgsujs7x…